VI International Symposium on Inflammatory Bowel Diseases

VI International Symposium on Inflammatory Bowel Diseases

Edited by  , Edited by  , Edited by  , Edited by  , Edited by 

List price: US$145.00

Currently unavailable

We can notify you when this item is back in stock

Add to wishlist

AbeBooks may have this title (opens in new window).

Try AbeBooks

Description

This book, the proceedings of Falk Symposium No. 123, VI International Symposium on Inflammatory Bowel Diseases, held in Istanbul, Turkey, on September 3-5, 2001, focuses on the issues and controversies pertinent to IBD in the 21st century. The achievements in medical, surgical, and in the basic sciences in the last twenty years since the first Jerusalem IBD Symposium are summarized in detail. Controversies with respect to the medical treatment of inflammatory bowel diseases are discussed. One section deals with surgical issues such as laparoscopic surgery in inflammatory bowel diseases, ileo-anal pouches and the surgical treatment of Crohn's disease. The last section is devoted to the biological treatment of IBD and to the needs both in medical science and in the clinic.
show more

Product details

  • Hardback | 256 pages
  • 158.75 x 234.95 x 19.05mm | 521g
  • Dordrecht, Netherlands
  • English
  • 2002 ed.
  • 256 p.
  • 0792387732
  • 9780792387732

Table of contents

List of Principal Contributors. Preface.
Section I: Aetiopathogenesis.
1. Is the immunologic response different in UC and CD? L. Mayer. 2. An update on lymphocyte activation and signal transduction in inflammation; A. Chawla, et al. 3. Are lessons from experimental models relevant for human IBD? C.O. Elson, et al. 4. ANCA/ASCA differential diagnosis between UC/CD? S. Joossens, et al. 5. Modalities to enhance restitution of mucosal injury; A.U. Diagnabeta.
Section II: Clinical Aspects.
6. Is the classification of Crohn'ns disease of any real value? D.B. Sachar. 7. What can be done to prevent bone deterioration? H.J.F. Hodgson. 8. Is the cancer risk different in ulcerative colitis and Crohn's disease? A. Ekbom.
Section III: Medical Treatment.
9. Efficacy of budesonide in ulcerative colitis; S. Bar-Meir. 10. Budesonide - Who really needs it? J. Schoelmerich. 11. Is metabolite monitoring essential for rational dosing of azathioprine and 6-mercaptopurine? W.J. Sandborn. 12. Immunosuppressors for inflammatory bowel disease - how long is long enough? R. Modigliani. 13. Crohn's disease should be treated aggressively (starting with immunomodulators); D.H. Present. 14. Current recommendation for use of probiotics; P. Gionchetti, et al. 15. Amelioration of experimental colitis by immunostimulatory DNA oligonucleotides; D. Rachmilewitz, et al. 16. Anti-TNF therapy: A fulfillment of great expectations; M.A. Kamm. 17. Infliximab: limited effects and troublesome side effects; J. Metzler, E.-F. Stange. 18. Thalidomide: Is it justified for usage in Crohn's disease? B.E. Sands. 19. Prevention of postoperative recurrence in Crohn's disease: Standard of practice; P. Rutgeerts. 20. Post-operative maintenance medications are useful in patients with Crohn's disease - CON; B.G. Feagan.
Section IV: Surgical Treatment.
21. When to resect and when to do stricturoplasty for Crohn's disease of the small intestine - a review; V.W. Fazio. 22. Ileo anal pouches for IBD State of the art 2001; N. Mortensen. 23. Laparoscopic colorectal surgery: the case against; M.G.W. Kettlewell.
Section V: Past to future.
24. Main achievements since 1st Jerusalem IBD symposium in September, 1981; J.E. Lennard-Jones. 25. T lymphocyte apoptosis: restoring mucosal immunological imbalance in Crohn's disease by cytokine-targeted therapy; J.M.H. Van den Brande, et al. 26. Investing in the future of IBD research: If I had ten million dollars how would I spend it? D.K. Podolsky.
Index.
show more